Exchange: NASDAQ·Updated 02:04 PM EDT
News
all
press releases
Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates
Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of 0.00% and -35.48%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
More News
Fortrea Holdings Inc. (FTRE) Surpasses Q2 Earnings and Revenue Estimates
Fortrea Holdings Inc. (FTRE) delivered earnings and revenue surprises of +27.78% and +4.62%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
ABUS Stock Rallies Ahead Of Big Payout From Moderna Settlement This Week
Arbutus expects to receive around $179 million from Moderna.
Stocktwits
Could Roivant Sciences Be a Multibagger Stock Over the Next 5 Years?
Key PointsRoivant Sciences anticipates three commercial launches over the next few years, led by brepocitinib...
Nasdaq News: Markets
Biotech and Biologics Break Out: These Tiny Stocks Are Suddenly Dominating the Market Conversation
Emerging biotech and biologics names exploded onto traders’ radar Wednesday as a wave of clinical milestones, regulatory momentum, strategic acquisitions, and high-volume technical breakouts fueled aggressive speculation across the sector. $HCWB, $TGNT, $KBLB, $SLS, $RKDA, $ROIV, $SLXN
24-7 Market News
TAT Technologies Posts Upbeat Q1 Earnings, Joins Roivant Sciences, Immunitybio And Other Big Stocks Moving Higher On Wednesday
TAT Technologies Ltd (TATT) reported better-than-expected Q1 results, sending shares up 11.7%. Other big gainers include IMVT, SLS, TE, VUZI, ROIV, POET, ARM, AMC, ALAB, DSGN, and TLN.read more...
Benzinga
Roivant Sciences Reports Q4 2026 Results: Full Earnings Call Transcript
read more...
Benzinga
ROIV Stock Nears Record High: Moderna Settlement Drives Q4 Profit, But Pipeline Catalysts Keep Retail Interested
The biotech firm delivered a fourth-quarter profit compared to loss estimates and unveiled promising milestone updates across its autoimmune disease pipeline.
Stocktwits
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates
Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of -41.18% and -8.56%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Montes Archimedes Acquisition (ROIV) Upgraded to Buy: Here's Why
Montes Archimedes Acquisition (ROIV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks

Advertisement|Remove ads.